The Biostatistics and Bioinformatics Core B will provide statistics and bioinformatics support and expertise in experimental design, data analysis and interpretation ofthe results as needed by the Projects and other Cores to achieve their Specific Aims. The studies in this POl require a variety of statistical and bioinformatic data analysis strategies such as modeling time course experiment data, tesfing synergisfic effect of kinase inhibitor combination, and analyzing genomic profiling data of RNA expression and DNA copy number. In addition. Core B will develop and maintain a bioinformatics infrastructure to enable collaboration and data sharing among research projects. This infrastructure includes: 1) a gene signature database 2) a somafic mutation database and functional characterization tools, and 3) a virtual cell line repository. A broad range of bioinformatics, computational, and statistical techniques will be applied to create this infrastructure.
The Biostatistics and Bioinformatics Core B forms an integral part ofthe P01 and will provide services that are essential for many of the different projects within the POl, assisting the POl investigators in their achievement of the overall research objective: developing new targets for therapy for carcinomas of the lung.
|Yu, Helena A; Arcila, Maria E; Harlan Fleischut, Megan et al. (2014) Germline EGFR T790M mutation found in multiple members of a familial cohort. J Thorac Oncol 9:554-8|
|Meador, Catherine B; Micheel, Christine M; Levy, Mia A et al. (2014) Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res 20:2264-75|
|Valiente, Manuel; Obenauf, Anna C; Jin, Xin et al. (2014) Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156:1002-16|
|de Bruin, Elza C; Cowell, Catherine; Warne, Patricia H et al. (2014) Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov 4:606-19|
|Rekhtman, Natasha; Borsu, Laetitia; Reva, Boris et al. (2014) Unsuspected collision of synchronous lung adenocarcinomas: a potential cause of aberrant driver mutation profiles. J Thorac Oncol 9:e1-3|
|Yu, H A; Arcila, M E; Hellmann, M D et al. (2014) Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 25:423-8|
|Lovly, Christine M; McDonald, Nerina T; Chen, Heidi et al. (2014) Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 20:1027-34|
|Yu, Helena A; Riely, Gregory J; Lovly, Christine M (2014) Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res 20:5898-907|
|Pirazzoli, Valentina; Nebhan, Caroline; Song, Xiaoling et al. (2014) Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep 7:999-1008|
|Haq, Rizwan; Fisher, David E; Widlund, Hans R (2014) Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res 20:2257-63|
Showing the most recent 10 out of 59 publications